Evidence Hub

Omega 3 Fatty Acids in the Treatment of Children With Autism Spectrum Disorders

ClinicalTrials.gov · COMPLETED, 2010

17 participants

Abstract

Published studies on omega 3 fatty acids in the treatment of bipolar disorder and schizophrenia have shown reductions in time to recurrence, a decrease in the positive and negative symptoms of schizophrenia, and improvements in Clinical Global Impression Scale, Young Mania Rating Scale, and HAM-D scores. The following are the hypotheses:

* Omega 3 fatty acids will be superior to placebo in the acute treatment of global autism.

* Omega 3 fatty acids will be superior to placebo in improving aggression and irritability associated with autism.

* Omega 3 fatty acids will be superior to placebo in improving functional ability.

Conditions: Autism.

Primary outcome: Clinical Global Impression Scale(CGI)- Improvement; Aberrant Behavior Checklist (ABC); Vineland Adaptive Behavior Scale.

Enrollment: 17 participants.

How strong is the evidence?

Evidence Hub reads this as a clinical trial, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 17 participants or records.

How the five levels of evidence work. The level is assigned automatically from the abstract and can be wrong, so check the paper.

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free